Immunization of Humans with Polyribophosphate, the Capsular Antigen of Hemophilus influenzae, Type b
Open Access
- 1 January 1972
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 51 (1) , 39-44
- https://doi.org/10.1172/jci106794
Abstract
In human volunteers, single injections of purified polyribophosphate elicited antibodies detectable by passive hemagglutination and by serum bactericidal and opsonizing activities against viable Hemophilus influenzae, type b. All three activities rose by 2 wk to maximal levels, at which they remained for at least 6 months. Doses of 1 μg elicited antibody responses in nearly all recipients; higher doses of the antigen, however, produced larger increases in titer. Booster doses of 1 μg given at 6 months did not further increase the antibody titers. A tuberculin-like response was often observed at the site of injections given intradermally.Keywords
This publication has 8 references indexed in Scilit:
- Human Serum Activities against Hemophilus influenzae, Type bJournal of Clinical Investigation, 1972
- The Clinical Importance of Hemophilus influenzae Infections in ChildrenPediatric Clinics of North America, 1970
- Cutaneous Reactions and Antibody Response to Meningococcal Group C Polysaccharide Vaccines in ManThe Journal of Infectious Diseases, 1970
- Prevention of Meningococcal Disease by Group C Polysaccharide VaccineNew England Journal of Medicine, 1970
- Secondary Antibody Responses in Haptenic Systems: Cell Population Selection by AntigenThe Journal of Immunology, 1967
- Further Studies on PolyribophosphateJournal of Biological Chemistry, 1961
- POLYRIBOPHOSPHATE, THE TYPE-SPECIFIC SUBSTANCE OF HEMOPHILUS INFLUENZAE, TYPE bJournal of Biological Chemistry, 1953
- PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENTJournal of Biological Chemistry, 1951